Geron Corporation (GERN)
$1.20-1.64%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $770M
- Beta
- 0.61
- P/E (TTM)
- -12.04
- Short % float
- 13.79%
- Days to cover
- 7.4
- SI change
- -10.6%
- 1W
- -0.83%
- 1M
- -12.41%
- vs SPY 1W
- -0.69%
- vs SPY 1M
- -14.91%
Industry peers
FMP comparable companies · ranked by market cap
- INCYSELLIncyte Corporation$22.0BBEARQ 13$108.62-2.46%
- SLSSELLSELLAS Life Sciences Group, Inc.$2.3BRECOVERYQ -8$12.41+4.02%
- COAGSELLHemab Therapeutics Holdings, Inc. Common Stock$1.4BQ -10$29.80-1.94%
- DMRASELLDamora Therapeutics, Inc.$1.1BCRISISQ -5$18.56-8.39%
- RIGLBUYRigel Pharmaceuticals, Inc.$872MBULLQ 9$47.14-3.42%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on GERN?
- LOPJLB’s latest quantitative signal on Geron Corporation (GERN) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is GERN in?
- Geron Corporation (GERN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Geron Corporation (GERN) do?
- Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid he…